Cargando…

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

BACKGROUND: Colorectal cancer is a major public health issue worldwide. Interleukin-17 (IL-17) and Th17 (T-helper cell type 17)-related molecules are involved in tumor development and in resistance to bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody used in association wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lereclus, Emilie, Tout, Mira, Girault, Alban, Baroukh, Nadine, Caulet, Morgane, Borg, Christophe, Bouché, Olivier, Ternant, David, Paintaud, Gilles, Lecomte, Thierry, Raoul, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368920/
https://www.ncbi.nlm.nih.gov/pubmed/28347290
http://dx.doi.org/10.1186/s12885-017-3210-z
_version_ 1782518020683333632
author Lereclus, Emilie
Tout, Mira
Girault, Alban
Baroukh, Nadine
Caulet, Morgane
Borg, Christophe
Bouché, Olivier
Ternant, David
Paintaud, Gilles
Lecomte, Thierry
Raoul, William
author_facet Lereclus, Emilie
Tout, Mira
Girault, Alban
Baroukh, Nadine
Caulet, Morgane
Borg, Christophe
Bouché, Olivier
Ternant, David
Paintaud, Gilles
Lecomte, Thierry
Raoul, William
author_sort Lereclus, Emilie
collection PubMed
description BACKGROUND: Colorectal cancer is a major public health issue worldwide. Interleukin-17 (IL-17) and Th17 (T-helper cell type 17)-related molecules are involved in tumor development and in resistance to bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody used in association with chemotherapy in metastatic colorectal cancer. Some studies have previously shown that IL-17A and IL-17F polymorphisms, respectively rs2275913 and rs763780, are associated with gastric or colorectal cancer risk. Here we aimed at studying the influence of IL-17A-related individual factors on overall survival and progression-free survival in patients with metastatic colorectal cancer treated with a bevacizumab-based chemotherapy. METHODS: Pre-treatment serum biomarkers were retrospectively evaluated in 122 metastatic colorectal cancer patients treated by bevacizumab in combination with chemotherapy at 2-weeks intervals in a prospective cohort study (NCT00489697). The polymorphisms of IL-17A and IL-17F were analyzed by polymerase chain reaction - restriction fragment length polymorphism. Serum concentrations of Th17-related cytokines were measured by MultiPlex. The impact of individual parameters on overall survival and progression-free survival was assessed using multivariate Cox models. RESULTS: High baseline IL-17A serum concentrations were significantly associated with shorter progression-free survival [p = 0.043]. Other baseline serum Th17-related cytokines and polymorphisms of IL-17 were not associated with overall survival or progression-free survival. CONCLUSIONS: In this ancillary study, baseline serum IL-17A concentration is the only Th17/IL-17 related factor that was significantly associated with the response of patients with metastatic colorectal cancer to bevacizumab. But this main significant result is highly dependent on one case which, if left out, weakens the data. Other clinical studies are required to confirm this association. TRIAL REGISTRATION: NCT00489697. June 20, 2007.
format Online
Article
Text
id pubmed-5368920
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53689202017-03-30 A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen Lereclus, Emilie Tout, Mira Girault, Alban Baroukh, Nadine Caulet, Morgane Borg, Christophe Bouché, Olivier Ternant, David Paintaud, Gilles Lecomte, Thierry Raoul, William BMC Cancer Research Article BACKGROUND: Colorectal cancer is a major public health issue worldwide. Interleukin-17 (IL-17) and Th17 (T-helper cell type 17)-related molecules are involved in tumor development and in resistance to bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody used in association with chemotherapy in metastatic colorectal cancer. Some studies have previously shown that IL-17A and IL-17F polymorphisms, respectively rs2275913 and rs763780, are associated with gastric or colorectal cancer risk. Here we aimed at studying the influence of IL-17A-related individual factors on overall survival and progression-free survival in patients with metastatic colorectal cancer treated with a bevacizumab-based chemotherapy. METHODS: Pre-treatment serum biomarkers were retrospectively evaluated in 122 metastatic colorectal cancer patients treated by bevacizumab in combination with chemotherapy at 2-weeks intervals in a prospective cohort study (NCT00489697). The polymorphisms of IL-17A and IL-17F were analyzed by polymerase chain reaction - restriction fragment length polymorphism. Serum concentrations of Th17-related cytokines were measured by MultiPlex. The impact of individual parameters on overall survival and progression-free survival was assessed using multivariate Cox models. RESULTS: High baseline IL-17A serum concentrations were significantly associated with shorter progression-free survival [p = 0.043]. Other baseline serum Th17-related cytokines and polymorphisms of IL-17 were not associated with overall survival or progression-free survival. CONCLUSIONS: In this ancillary study, baseline serum IL-17A concentration is the only Th17/IL-17 related factor that was significantly associated with the response of patients with metastatic colorectal cancer to bevacizumab. But this main significant result is highly dependent on one case which, if left out, weakens the data. Other clinical studies are required to confirm this association. TRIAL REGISTRATION: NCT00489697. June 20, 2007. BioMed Central 2017-03-27 /pmc/articles/PMC5368920/ /pubmed/28347290 http://dx.doi.org/10.1186/s12885-017-3210-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lereclus, Emilie
Tout, Mira
Girault, Alban
Baroukh, Nadine
Caulet, Morgane
Borg, Christophe
Bouché, Olivier
Ternant, David
Paintaud, Gilles
Lecomte, Thierry
Raoul, William
A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen
title A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen
title_full A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen
title_fullStr A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen
title_full_unstemmed A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen
title_short A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen
title_sort possible association of baseline serum il-17a concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368920/
https://www.ncbi.nlm.nih.gov/pubmed/28347290
http://dx.doi.org/10.1186/s12885-017-3210-z
work_keys_str_mv AT lereclusemilie apossibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT toutmira apossibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT giraultalban apossibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT baroukhnadine apossibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT cauletmorgane apossibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT borgchristophe apossibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT boucheolivier apossibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT ternantdavid apossibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT paintaudgilles apossibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT lecomtethierry apossibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT raoulwilliam apossibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT lereclusemilie possibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT toutmira possibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT giraultalban possibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT baroukhnadine possibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT cauletmorgane possibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT borgchristophe possibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT boucheolivier possibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT ternantdavid possibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT paintaudgilles possibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT lecomtethierry possibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen
AT raoulwilliam possibleassociationofbaselineserumil17aconcentrationswithprogressionfreesurvivalofmetastaticcolorectalcancerpatientstreatedwithabevacizumabbasedregimen